Provectus Biopharmaceuticals' Phase 1 PV-10 Data on Liver Cancer Presented at 6th Asia-Pacific Primary Liver Cancer Expert Meeting

By: via Benzinga
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com ), a clinical-stage oncology and dermatology biopharmaceutical ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.